Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics
Reason given: Low/slow accrual
Key facts
- Where
- Jacksonville, Rochester, and Scottsdale, United StatesSee the 3 sites
Where in United States
- Mayo ClinicJacksonville, United StatesNo longer taking part
- Mayo ClinicRochester, United StatesNo longer taking part
- Mayo ClinicScottsdale, United StatesNo longer taking part
Trial details
- Who runs it
- Mayo Clinic
- Trial code
- NCT05819827
- Record updated
- 27 April 2025
- Original description
The objective of this pilot cohort study is to investigate associations between CIN and changes in gut microbiome composition profiles.Read full original descriptionShow less
Investigation of Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics
The objective of this pilot cohort study is to investigate associations between CIN and changes in gut microbiome composition profiles.
Inclusion: at least 20 years of age; last chemotherapy more than 3 years ago; scheduled to receive either moderate to highly emetogenic chemotherapy with or without targeted therapies including immunotherapies) or immunotherapies/targeted therapies alone that can lead to toxicity symptoms for example, nausea and fatigue; Patients receiving chemotherapy and/or immunotherapy treatment at a Mayo Clinic infusion center or an infusion center outside of Mayo Clinic.
Exclusion: concurrent radiation therapy; concurrent antibiotic treatment; concurrent oncolytic virus treatment.